ATE535547T1 - Vernetzte antikörper - Google Patents

Vernetzte antikörper

Info

Publication number
ATE535547T1
ATE535547T1 AT05744346T AT05744346T ATE535547T1 AT E535547 T1 ATE535547 T1 AT E535547T1 AT 05744346 T AT05744346 T AT 05744346T AT 05744346 T AT05744346 T AT 05744346T AT E535547 T1 ATE535547 T1 AT E535547T1
Authority
AT
Austria
Prior art keywords
cross
linked antibodies
antibodies
fragments
linked
Prior art date
Application number
AT05744346T
Other languages
English (en)
Inventor
Terence Seward Baker
Catherine Mckay
Timothy John Norman
John Robert Porter
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE535547T1 publication Critical patent/ATE535547T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT05744346T 2004-05-19 2005-05-17 Vernetzte antikörper ATE535547T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0411186.0A GB0411186D0 (en) 2004-05-19 2004-05-19 Biological products
PCT/GB2005/001950 WO2005113605A1 (en) 2004-05-19 2005-05-17 Cross-linked antibodies

Publications (1)

Publication Number Publication Date
ATE535547T1 true ATE535547T1 (de) 2011-12-15

Family

ID=32607598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05744346T ATE535547T1 (de) 2004-05-19 2005-05-17 Vernetzte antikörper

Country Status (9)

Country Link
US (1) US8053564B2 (de)
EP (1) EP1751192B1 (de)
JP (1) JP2008509885A (de)
AT (1) ATE535547T1 (de)
AU (1) AU2005245668A1 (de)
CA (1) CA2562701A1 (de)
ES (1) ES2375630T3 (de)
GB (1) GB0411186D0 (de)
WO (1) WO2005113605A1 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290567A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A Comb polymers
CN101356194B (zh) 2005-12-09 2013-06-12 Ucb医药有限公司 对人il-6具有特异性的抗体分子
EP2073820A4 (de) * 2006-09-15 2014-07-16 Belrose Pharma Inc Gezielte polymer-prodrugs mit multifunktionalen verknüpfern
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US9319225B2 (en) 2007-01-16 2016-04-19 Microsoft Technology Licensing, Llc Remote device waking using a multicast packet
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
US8968818B2 (en) 2009-02-21 2015-03-03 Covidien Lp Medical devices having activated surfaces
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8968733B2 (en) * 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
WO2010096649A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
US9273191B2 (en) 2009-02-21 2016-03-01 Sofradim Production Medical devices with an activated coating
US8877170B2 (en) * 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
EP2398941B1 (de) 2009-02-21 2016-07-13 Sofradim Production Vernetzte fasern und verfahren zu ihrer herstellung mittels extrusion
AU2010215202A1 (en) 2009-02-21 2011-10-13 Covidien Lp Crosslinked fibers and method of making same using UV radiation
AU2010215194A1 (en) 2009-02-21 2011-10-13 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
EP2398845B1 (de) 2009-02-21 2017-12-13 Sofradim Production Amphiphile verbindungen und daraus hergestellte selbstanordnende zusammensetzungen
US9375699B2 (en) 2009-02-21 2016-06-28 Sofradim Production Apparatus and method of reacting polymers by exposure to UV radiation to produce injectable medical devices
EP2398519A2 (de) 2009-02-21 2011-12-28 Sofradim Production Verbindungen und mit solvophoben linkern aktivierte medizinische vorrichtungen
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
ES2700442T3 (es) 2009-02-25 2019-02-15 Ucb Biopharma Sprl Método para producir anticuerpos
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2011023680A2 (en) 2009-08-24 2011-03-03 Cytos Biotechnology Ag Processes for the synthesis and purification of heterobifunctional cross-linkers
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0916881D0 (en) * 2009-09-25 2009-11-11 Electrophoretics Ltd Mass labels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (de) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1-antikörper
AU2011231246B2 (en) 2010-03-25 2015-05-21 Sofradim Production Surgical fasteners and methods for sealing wounds
EP2550031B1 (de) 2010-03-25 2015-08-19 Sofradim Production Medizinische vorrichtungen mit funktionellen klebstoffen
AU2011276443A1 (en) 2010-06-29 2013-01-31 Covidien Lp Microwave-powered reactor and method for in situ forming implants
WO2012001532A2 (en) 2010-07-01 2012-01-05 Sofradim Production Medical device with predefined activated cellular integration
AU2011284449B2 (en) 2010-07-27 2015-07-23 Sofradim Production Polymeric fibers having tissue reactive members
ME02734B (de) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antikörpermodule zur bindung an il-17a und il-17f
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重v區類抗體蛋白質之用途
CN103459366B (zh) * 2011-03-30 2015-04-15 富士胶片株式会社 聚醚化合物、使用了该聚醚化合物的固化剂以及该聚醚化合物的制造方法
BR112014006175B1 (pt) 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
US9803004B2 (en) 2011-11-11 2017-10-31 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP3288584A2 (de) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2-antikörper und antigenbindemittel zur behandlung von stoffwechselerkrankungen
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP6851322B2 (ja) 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
EA037092B1 (ru) 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
DK3359688T3 (da) 2015-10-05 2021-08-23 Biogen Ma Inc Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
MY207225A (en) 2015-10-27 2025-02-06 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
IL298686A (en) 2016-01-11 2023-01-01 Inhibrx Inc Multivalent and multispecific ox40-binding fusion proteins
CA3022494A1 (en) 2016-05-01 2017-11-09 Ucb Biopharma Sprl Affinity engineered serum protein carrier binding domain
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗pd-l1およびil-2サイトカイン
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
MY197324A (en) 2016-08-29 2023-06-13 Akamis Bio Ltd Adenovirus armed with bispecific t cell activator
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
EP3624848A1 (de) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Kombinationstherapien
JP7394628B2 (ja) 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
PE20201462A1 (es) 2017-09-05 2020-12-17 Gladiator Biosciences Inc Metodo de direccionamiento de exosomas
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
SG11202012312UA (en) 2018-06-18 2021-01-28 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
CN112601761A (zh) 2018-08-13 2021-04-02 印希比股份有限公司 结合ox40的多肽及其用途
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
EP3947457A1 (de) 2019-03-26 2022-02-09 ASLAN Pharmaceuticals Pte Ltd Behandlung mit verwendung von anti-il-13r-antikörper oder bindefragment davon
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
KR20220143869A (ko) 2020-02-21 2022-10-25 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
US20230174670A1 (en) 2020-05-14 2023-06-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
KR20230034361A (ko) 2020-07-02 2023-03-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도
CA3184724A1 (en) 2020-07-27 2022-02-03 Wenming REN Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof
US20230374158A1 (en) 2020-10-13 2023-11-23 Almirall, S.A. Bispecific molecules and methods of treatment using the same
US20230374148A1 (en) 2020-10-15 2023-11-23 UCB Biopharma SRL Binding molecules that multimerise cd45
GB202102227D0 (en) 2021-02-17 2021-03-31 UCB Biopharma SRL Antibodies
EP4331603A4 (de) 2021-04-25 2025-04-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-masp2-antikörper, antigenbindendes fragment davon und medizinische verwendung davon
EP4365200A4 (de) 2021-06-28 2025-04-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd40-antikörper, antigenbindendes fragment und medizinische verwendung davon
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
EP4393949A4 (de) 2021-08-25 2025-01-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmazeutische zusammensetzung mit fusionsprotein
CN117940453A (zh) 2021-09-15 2024-04-26 江苏恒瑞医药股份有限公司 特异性结合pd-1的蛋白及其医药用途
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗il13r抗體調配物
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
MX2024009715A (es) 2022-02-11 2024-08-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Inmunoconjugado y su uso del mismo.
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
EP4590335A1 (de) 2022-08-26 2025-07-30 ASLAN Pharmaceuticals Pte Ltd Hochkonzentrierte anti-il13r-antikörperformulierung
GB202214756D0 (en) 2022-10-07 2022-11-23 Univ Oxford Innovation Ltd Product
CA3273660A1 (en) 2022-11-28 2024-06-06 UCB Biopharma SRL TREATMENT FOR FIBROMYALGIA
JP2026502840A (ja) 2022-12-28 2026-01-27 スゥジョウ サンカディア バイオファーマシューティカルズ カンパニー リミテッド Cd40結合分子の組成物及び医薬的使用
JP2026510747A (ja) 2023-03-15 2026-04-10 シャンハイ マブジェン バイオテック リミテッド Pd-1/pvrig/tigit結合タンパク質を含む医薬組成物及びその医薬的使用
KR20260054696A (ko) 2023-08-16 2026-04-22 상하이 맙젠 바이오텍 리미티드 면역접합체를 포함하는 약학적 조성물 및 이의 용도
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
GB202403366D0 (en) 2024-03-08 2024-04-24 Univ Oxford Innovation Ltd Product
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies
TW202606759A (zh) 2024-08-02 2026-02-16 比利時商Ucb生物製藥公司 抗Gremlin-1抗體的調配物
WO2026057816A1 (en) 2024-09-13 2026-03-19 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935257A1 (de) * 1989-10-23 1991-04-25 Langhals Heinz Mit antikoerpern verknuepfte liposomen als traeger fuer einen gezielten transport von wirkstoffen und reagenzien - fluoreszenzmarkierung der transportwege und des wirkorts
US5262524A (en) 1990-03-09 1993-11-16 Hybritech Incorporated Method for the synthesis of trifunctional maleimide-antibody complex
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US6033884A (en) * 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US7524821B2 (en) * 2002-06-20 2009-04-28 University Of Maryland Biotechnology Institute Scaffolded maleimide clusters for multivalent peptide assembly
EP1534269B1 (de) 2002-07-19 2013-10-30 The General Hospital Corporation Oxim-konjugate und verfahren zu ihrer bildung und verwendung

Also Published As

Publication number Publication date
US8053564B2 (en) 2011-11-08
AU2005245668A1 (en) 2005-12-01
WO2005113605A1 (en) 2005-12-01
CA2562701A1 (en) 2005-12-01
US20080160017A1 (en) 2008-07-03
JP2008509885A (ja) 2008-04-03
ES2375630T3 (es) 2012-03-02
GB0411186D0 (en) 2004-06-23
EP1751192B1 (de) 2011-11-30
EP1751192A1 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
GB0411186D0 (en) Biological products
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY2018013I1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
MY154904A (en) Neuropilin antagonists
NO20055018D0 (no) Anti-amyolide antistoffer, sammensetninger, fremgangsmater og anvendelser
EP2423231A3 (de) PRLR-spezifischer Antikörper und Anwendung
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
EP2163562A3 (de) IL-1 beta bindende Antikörper und deren Fragmente
BR0306617B1 (pt) mecanismo de bocal variável, turbo carregador de exaustão equipado com o mesmo, e método de fabricação de turbo carregador de exaustão com mecanismo de bocal variável.
DE60310191D1 (de) Linearmotor und diesen verwendender linear-kompressor
WO2004042017A3 (en) Methods and compositions for increasing antibody production
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
PT1546734E (pt) Anticorpos monoclonais de amiloide beta n 11 truncados, composições, métodos e utilizações
EP1623011A4 (de) Von il-23p40-spezifischem immunglobulin abgeleitete proteine, zusammensetzungen, verfahren und verwendungen
WO2005003171A3 (en) Modified antibody fragments
TW200510459A (en) RG1 antibodies and uses thereof
BR0308211A (pt) Cumarinas úteis como biomarcadores
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
HRP20151252T4 (hr) Modificirani fab ulomci protutijela
EP2402373A3 (de) ANTI-EPHB4-Antikörper sowie Verfahren zu deren Verwendung
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2008019326A3 (en) Ephb3-specific antibody and uses thereof
DE50310143D1 (de) Fahrpedal
BRPI0412699A (pt) compostos e particulados hidrofóbicos e aplicações destes